A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer

Clinical trial NCT06678659 · RECRUITING

Trial details

NCT number: NCT06678659
Sponsor: Recursion Pharmaceuticals Inc.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Unresectable Locally Advanced Metastatic Cancers Relapsed/Refractory Lymphomas

Start date: 2024-11-21
Primary completion: 2028-10-30
Enrollment: 170

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.